# Azurity Pharmaceuticals, Inc. - Inspection Records

Source: https://www.keypedia.com/companies/azurity-pharmaceuticals-inc/be6c2042-21df-4e44-a30d-11c6629303d8

> Inspection records and compliance data for Azurity Pharmaceuticals, Inc. in Wilmington, Massachusetts. Access full analysis and detailed observations.

---

## Details

- Name: Azurity Pharmaceuticals, Inc.
- FEI Number: 3003395329
- City: Wilmington
- State: Massachusetts
- Country Name: United States
- Address Line 1: 841 Woburn St
- Zip Code: 01887

## Related Documents

- [FDA Inspection 1297348 - Azurity Pharmaceuticals, Inc. - 2025-12-12](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/624df1ea-7a53-4a00-8c3c-afb7e077a0e8) — source: FDA, date: December 12, 2025
- [FDA Inspection 1297348 - Azurity Pharmaceuticals, Inc. - 2025-12-12](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/7c93bd99-060c-47b1-906c-ce6cdfe7bf52) — classification: No Action Indicated (NAI), source: FDA, date: December 12, 2025
- [483 - Azurity Pharmaceuticals, Inc. - 2025-02-19](https://www.keypedia.com/records/483/azurity-pharmaceuticals-inc/fbd8eaca-fe0a-415e-8722-8c80ddd8f442) — source: FDA, date: February 19, 2025
- [FDA Inspection 1261303 - Azurity Pharmaceuticals, Inc. - 2025-02-19](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/5bc3e1cb-551b-4b19-8657-c5a1e0e2c087) — source: FDA, date: February 19, 2025
- [483 - Azurity Pharmaceuticals, Inc. - 2023-03-02](https://www.keypedia.com/records/483/azurity-pharmaceuticals-inc/3a26f0be-61a2-41f0-9deb-51eead2d9a04) — source: FDA, date: March 2, 2023
- [FDA Inspection 1199279 - Azurity Pharmaceuticals, Inc. - 2023-03-02](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/d81f0586-7c5d-4396-a80e-766283dec67c) — source: FDA, date: March 2, 2023
- [483 - Azurity Pharmaceuticals, Inc. - 2022-02-24](https://www.keypedia.com/records/483/azurity-pharmaceuticals-inc/2704437d-fff0-4d09-b5aa-59c63a5d39d3) — source: FDA, date: February 24, 2022
- [FDA Inspection 1163010 - Azurity Pharmaceuticals, Inc. - 2022-02-24](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/12a62341-3a2c-4ccd-af8a-ac1ef6bbb9ad) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 24, 2022
- [483 - Azurity Pharmaceuticals, Inc. - 2020-01-15](https://www.keypedia.com/records/483/azurity-pharmaceuticals-inc/5112db17-449d-4ac7-802d-0dd69b3bd25b) — source: FDA, date: January 15, 2020
- [FDA Inspection 1100022 - Azurity Pharmaceuticals, Inc. - 2019-07-26](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/824bff13-d825-4069-b07d-12705e842fb0) — classification: No Action Indicated (NAI), source: FDA, date: July 26, 2019
- [EIR - Azurity Pharmaceuticals, Inc. - 2019-04-19](https://www.keypedia.com/records/eir/azurity-pharmaceuticals-inc/9a78ab74-7a67-4339-9e11-71498e3a5517) — source: FDA, date: April 19, 2019
- [EIR - Azurity Pharmaceuticals, Inc. - 2017-12-20](https://www.keypedia.com/records/eir/azurity-pharmaceuticals-inc/d0036b3f-fbc3-465f-98b8-8381b746748d) — source: FDA, date: December 20, 2017
- [FDA Inspection 970690 - Azurity Pharmaceuticals, Inc. - 2016-04-19](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/406cc9d4-18de-434c-8f96-b6a0e230e396) — classification: No Action Indicated (NAI), source: FDA, date: April 19, 2016
- [FDA Inspection 970690 - Azurity Pharmaceuticals, Inc. - 2016-04-19](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/5756e04c-0ea5-484f-8186-33c970bbf441) — classification: No Action Indicated (NAI), source: FDA, date: April 19, 2016
- [FDA Inspection 970690 - Azurity Pharmaceuticals, Inc. - 2016-04-19](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/d7596e4b-a5e0-4350-8e79-09c75eb1d79a) — classification: No Action Indicated (NAI), source: FDA, date: April 19, 2016
- [FDA Inspection 865746 - Azurity Pharmaceuticals, Inc. - 2014-01-29](https://www.keypedia.com/records/fda_inspections/azurity-pharmaceuticals-inc/ddf3c586-cea3-4b42-a9a0-2c62a45dff9b) — classification: Voluntary Action Indicated (VAI), source: FDA, date: January 29, 2014

## Related Companies

- [Dexcowin Co. Ltd.](https://www.keypedia.com/companies/dexcowin-co-ltd/95b6ec0f-e5d8-4d7d-8eb8-d5d31e4633c5)
- [Fujifilm Corporation](https://www.keypedia.com/companies/fujifilm-corporation/6310bc48-89ef-4f36-98c9-1e0294a89e06)
- [Inotiv Inc](https://www.keypedia.com/companies/inotiv-inc/be017b67-b3f0-402d-8a03-b124ca114fa6)
- [Velocity Pharma LLC](https://www.keypedia.com/companies/velocity-pharma-llc/95cf109a-29fe-428d-9b69-52a257c94f0c)
- [Reproductive Technologies, Inc.](https://www.keypedia.com/companies/reproductive-technologies-inc/81a46c28-125d-4e9e-ba8b-1d521dff2b44)
- [Utah Cord Bank LLC](https://www.keypedia.com/companies/utah-cord-bank-llc/743c0464-dbbc-49bb-aa26-68e0f9dc8db6)
- [Meditco, Inc. D.B.A. Phoenicia Specialty Foods](https://www.keypedia.com/companies/meditco-inc-dba-phoenicia-specialty-foods/4296281d-f772-4072-b1de-c83a12281fe2)
- [Syneos Health](https://www.keypedia.com/companies/syneos-health/a2842cea-ef97-4a3d-92be-6af32c00ccaf)
- [Abaxis Inc](https://www.keypedia.com/companies/abaxis-inc/98392f88-354f-4be2-b781-a75f289470a2)
- [Advanced Instrumentations, Inc.](https://www.keypedia.com/companies/advanced-instrumentations-inc/4d9b9f1e-df18-4b76-ba69-fbb66b575fc4)

## Related Officers

- [Principal](https://www.keypedia.com/people/christopher-janik/2803fa51-5259-4632-93ad-c6f038bd2fd4)
- [Arizona Market President](https://www.keypedia.com/people/john-p-mistler/7b2d423d-46cc-48bd-aa5a-4ae794888060)
- [Regulatory Officer I n ve s tig ato r ](https://www.keypedia.com/people/dien-nguyen/90e26f94-e417-4c64-ab44-3674387b82b4)
- [Investigator](https://www.keypedia.com/people/erik-w-koester/2bbab081-6783-40a1-83c1-b219bde22bd1)